09.12.2023 International Scientific Journal "Science and Innovation". Series D. Volume 2 Issue 12
Abstract. This review article examines the effect of various therapeutic interventions on autonomic dysfunction that characterizes chronic renal failure in CKD. It has been shown that drugs acting on the renin-angiotensin system, as well as central sympatholytics, improve autonomic cardiovascular control
Keywords: autonomic nervous system, sympathetic activity, parasympathetic activity, chronic renal failure, heart rate variability
1. Polyanskaya E.A. Atrial fibrillation and cardiorenal syndrome: clinico-pathogenetic relationships and prognostic determinants: Author's thesis. ...doctor of medical sciences. Perm, 2023; 48. 2. Samorodskaya N.A. Estimation of stress influence on heart rhythm variability in hypertensive disease. Vestnik VSU. 2022; 19 (1): 92-94. 3. Turakhia M.P. Chronic kidney disease and arrhythmias: results of the KDIGO conference on controversial issues. Nephrology. 2019. 23 (2): 1840. 4. Yabluchansky N.I., Martyrnenko A.V. Heart rate variability to help the practical doctor. Kharkov, 2010; 131. Adair K.E., Bowden R.G. Ameliorating Chronic Kidney Disease Using a Whole Food Plant-Based Diet. Nutrients. 2020; 12: 1007. 5. Ananthapanyasut W., Napan S., Rudolph E.H., Harindhanavudhi T., Ayash H., Guglielmi K.E., Lerma E.V. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 173–181. 6. Anderson T.J., Grégoire J., Pearson G.J. et al. 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol. 2016; 32(11): 1263–1282. 7. Appel M.L.,Berger R.D., Saul J.P. et al. Beat to beat variability in cardiovascular variables: Noise or music? J. Am. Coil Cardiol. 1989; 14: 1139-1148. 8. Astor B.C., Fox C.H. et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am. J. Kidney Dis. 2014; 63(5): 713–735. 9. Astor B.C., Matsushita K., Gansevoort R.T. et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease: a collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011; 79(12): 1331–1340. 10. Chan K.E., Giugliano R.P., Patel M.R. et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J. Am. Coll. Cardiol. 2016; 67(24): 2888–2899. 11. Chapin E., Zhan M., Hsu V.D., Seliger S.L., Walker L.D., Fink J.C. Adverse safety events in chronic kidney disease: the frequency of “multiple hits”. Clin J Am Soc Nephrol. 2010; 5(1): 95–101. 12. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129: 837–847. 13. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., Wiltse C., Wright T.J., MOXCON Investigators Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur. J. Heart. Fail. 2013; 5(5): 659–667. 14. De Ferrary G.M., Vanjli E., Schwartz P.J. Cardiac vagal activity, myokardial ischemia and sudden death.Cardiac electrophysiology. From cell to bedside. Philadeiphia: W.B. Snnders, 1995; 422-434. 15. Dell'oro R., Gronda E., Seravalle G., Costantino G., Alberti L. et al. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Final 43-month study report. J. Hypertens. 2017 ;35(12): 2532–2536. 16. Ding W.Y. et al. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. Eur. J. Clin. Invest. 2022; 52 (6): e13745. 17. Eckardt K.U., Coresh J., Devuyst O., Johnson R.J., Kottgen A. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013; 382: 158–169. 18. Gansevoort R.T., Matsushita K., van der Velde M. et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011; 80(1): 93–104. 19. Genovese G., Friedman D.J., Ross M.D. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993): 841–845. 20. Grassi G., Bertoli S., Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2012; 21(1): 46–51. 21. Hansrivijit P., Oli S., Khanal R., Ghahramani N., Thongprayoon C., Cheungpasitporn W. Mediterranean Diet and the Risk of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Nephrology. 2020; 25: 913–918. 22. Hou Y.-C., Lu C.-L., Lu K.-C. Mineral Bone Disorders in Chronic Kidney Disease. Nephrology. 2018; 23: 88–94. 23. Ikizler T.A., Burrowes J.D., Byham-Gray L.D., Campbell K.L., Carrero J.-J., Chan W., Fouque D., Friedman A.N., Ghaddar S., Goldstein-Fuchs D.J., et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am. J. Kidney Dis. 2020; 76: S1–S107. 24. Jha V., Garcia-Garcia G., Iseki K. et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260–272. 25. Ketteler M., Block G.A., Evenepoel P., Fukagawa M., Herzog C.A. et al. Executive Summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s Changed and Why It Matters. Kidney Int. 2017; 92: 26–36. 26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3(1): 1–150. 27. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013; 3(3): 259–305. 28. Kolloch R., Legler U.F., Champion A., Cooper-Dehoff R.M., Handberg E., Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur. Heart. J. 2008; 29(10): 1327–1334. 29. Konigsbrugge O., Posch F., Antlanger M., Kovarik J., Klauser-Braun R. et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI). PLoS One. 2017; 12: e0169400. 30. Marcos E.G. et al. Relation of renal dysfunction with incident atrial fibrillation and cardiovascular morbidity and mortality: The PREVEND study. Europace. 2017; 19 (1): 1930-1936. 31. Matsushita K., Coresh J., Sang Y. et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015; 3(7): 514–525. 32. Mills K.T., Xu Y., Zhang W. et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015; 88(5): 950–957. 33. Naik R.P., Derebail V.K., Grams M.E. et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014; 312(20): 2115–2125. 34. Narsipur S.S., Srinivasan B., Singh B. Effect of simvastatin use on autonomic function in patients with end-stage renal disease. Cardiovasc. Hematol. Disord. Drug. Targets. 2011; 11(1): 53–57. 35. O’Seaghdha C.M., Parekh R.S., Hwang S.J. et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet. 2011; 20 (12): 2450–2456. 36. Ruocco G., Palazzuoli А., Ter Maaten J.M. The role of the kidney in acute and chronic heart failure. Heart Fail Rev. 2020; 25 (1): 107-118. 37. Sato R., Mizuno M., Miura T. et al. Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure. J Hypertens. 2013; 31(6): 1233–1238. 38. Shang W., Li L., Huang S., Zeng R., Huang L., Ge S., Xu G., Sun J. Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoS One. 2016; 11: e0155581. 39. Siddiqi L., Joles J.A., Oey P.L., Blankestijn P.J. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens. 2011; 29(11): 2176–2180. 40. Sztajzel J. Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. Swiss Med Wkly. 2004; 134: 514–522. 41. Tonelli M., Wanner C.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014; 160(3): 182. 42. US Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2019; 69(3 Suppl 1): A7–A8. 43. Vonend O., Marsalek P., Russ H., Wulkow R., Oberhauser V., Rump L.C. Moxonidine treatment of hypertensive patients with advanced renal failure. J. Hypertens. 2003; 21(9): 1709–1717. 44. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur. Heart J. 2018; 39(33): 3021–3104. 45. Zoccali C., Seravalle G., Grassi G. Sympathoinhibitory effects of statins in chronic kidney disease: are they clinically relevant? J. Hypertens. 2011; 29(11): 2064–2067.
SCIENCE & INNOVATION